Antigenics To Stimulate Immunology Projects With Stimulon From Aquila
Antigenics expects to boost its infectious disease and autoimmune product development with Aquila's vaccine adjuvant Stimulon QS-21 following a proposed merger.
Antigenics expects to boost its infectious disease and autoimmune product development with Aquila's vaccine adjuvant Stimulon QS-21 following a proposed merger.